ⅢA期非小细胞肺癌的围手术期免疫化疗：对未来方向的见解 - Suppr

Suppr

超能文献

Perioperative immunochemotherapy in stage IIIA non-small cell lung cancer: insights on the path forward.

作者信息

Soh Junichi

机构信息

Department of Thoracic Surgery, Osaka Metropolitan University Graduate School of Medicine, Osaka, Japan.

出版信息

Transl Lung Cancer Res. 2025 May 30;14(5):1882-1886. doi: 10.21037/tlcr-2025-202. Epub 2025 May 28.

DOI:10.21037/tlcr-2025-202

PMID:40535080

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12170134/

Abstract

摘要

相似文献

Perioperative immunochemotherapy in stage IIIA non-small cell lung cancer: insights on the path forward.ⅢA期非小细胞肺癌的围手术期免疫化疗：对未来方向的见解

Transl Lung Cancer Res. 2025 May 30;14(5):1882-1886. doi: 10.21037/tlcr-2025-202. Epub 2025 May 28.

Perioperative chemotherapy and nivolumab in non-small-cell lung cancer (NADIM): 5-year clinical outcomes from a multicentre, single-arm, phase 2 trial.多中心、单臂、2 期临床试验中，非小细胞肺癌（NADIM）围手术期化疗联合纳武利尤单抗的 5 年临床结果。

Lancet Oncol. 2024 Nov;25(11):1453-1464. doi: 10.1016/S1470-2045(24)00498-4. Epub 2024 Oct 14.

Delta-radiomics features combined with haematological index predict pathological complete response after neoadjuvant immunochemotherapy in resectable non-small cell lung cancer.Delta放射组学特征联合血液学指标预测可切除非小细胞肺癌新辅助免疫化疗后的病理完全缓解

Clin Radiol. 2025 Jul;86:106906. doi: 10.1016/j.crad.2025.106906. Epub 2025 Apr 7.

Immunotherapy in operable non-small cell lung cancer: a systematic review and network meta-analysis of efficacy between neoadjuvant immunochemotherapy and perioperative immunotherapy.可手术非小细胞肺癌的免疫治疗：新辅助免疫化疗与围手术期免疫治疗疗效的系统评价和网状荟萃分析

J Thorac Dis. 2024 Oct 31;16(10):6699-6712. doi: 10.21037/jtd-24-287. Epub 2024 Oct 11.

Video-Assisted Thoracoscopic Surgery Versus Thoracotomy Following Neoadjuvant Immunochemotherapy in Resectable Stage III Non-Small Cell Lung Cancer Among Chinese Populations: A Multi-Center Retrospective Cohort Study.中国人群中可切除Ⅲ期非小细胞肺癌新辅助免疫化疗后电视辅助胸腔镜手术与开胸手术的比较：一项多中心回顾性队列研究

Clin Lung Cancer. 2024 Jul;25(5):395-406.e5. doi: 10.1016/j.cllc.2024.03.008. Epub 2024 Apr 2.

Preoperative immunochemotherapy for locally advanced non-small cell lung cancer: an analysis of the clinical outcomes, optimal number of cycles, and peripheral immune markers.局部晚期非小细胞肺癌的术前免疫化疗：临床结局、最佳周期数及外周免疫标志物分析

Transl Lung Cancer Res. 2022 Dec;11(12):2364-2381. doi: 10.21037/tlcr-22-439.

Four-year outcomes with perioperative toripalimab plus chemotherapy in resectable stage III non-small cell lung cancer (NeoTAP01 study).围手术期托瑞帕利单抗联合化疗用于可切除Ⅲ期非小细胞肺癌的4年结局（NeoTAP01研究）

J Thorac Dis. 2025 May 30;17(5):2947-2957. doi: 10.21037/jtd-2024-2266. Epub 2025 May 28.

Interim analysis of the efficiency and safety of neoadjuvant PD-1 inhibitor (sintilimab) combined with chemotherapy (nab-paclitaxel and carboplatin) in potentially resectable stage IIIA/IIIB non-small cell lung cancer: a single-arm, phase 2 trial.新辅助 PD-1 抑制剂（信迪利单抗）联合化疗（白蛋白紫杉醇联合卡铂）治疗可切除 IIIA/IIIB 期非小细胞肺癌的疗效和安全性的初步分析：一项单臂、Ⅱ期临床试验。

J Cancer Res Clin Oncol. 2023 Feb;149(2):819-831. doi: 10.1007/s00432-021-03896-w. Epub 2022 Feb 22.

Short-term outcomes of robot-assisted versus video-assisted thoracoscopic surgery for non-small cell lung cancer patients with neoadjuvant immunochemotherapy: a single-center retrospective study.新辅助免疫化疗的非小细胞肺癌患者行机器人辅助与电视辅助胸腔镜手术的短期疗效比较：单中心回顾性研究。

Front Immunol. 2023 Jul 11;14:1228451. doi: 10.3389/fimmu.2023.1228451. eCollection 2023.

Two versus three to four cycles of neoadjuvant immunochemotherapy for stage IB-IIIB non-small cell lung cancer: a real-world study.IB-IIIB期非小细胞肺癌新辅助免疫化疗两个周期与三至四个周期的比较：一项真实世界研究

J Thorac Dis. 2025 Feb 28;17(2):1028-1041. doi: 10.21037/jtd-2024-2256. Epub 2025 Feb 27.

本文引用的文献

An international and multidisciplinary EORTC survey on resectability of stage III non-small cell lung cancer.一项关于Ⅲ期非小细胞肺癌可切除性的国际多学科欧洲癌症研究与治疗组织（EORTC）调查。

Lung Cancer. 2025 Jan;199:108061. doi: 10.1016/j.lungcan.2024.108061. Epub 2024 Dec 15.

A Tumor-Naïve ctDNA Assay Detects Minimal Residual Disease in Resected Stage II or III Colorectal Cancer and Predicts Recurrence: Subset Analysis from the GALAXY Study in CIRCULATE-Japan.一种未接触肿瘤的循环肿瘤DNA检测法可检测II期或III期切除结直肠癌中的微小残留病并预测复发：来自日本CIRCULATE研究中GALAXY研究的亚组分析

Clin Cancer Res. 2025 Jan 17;31(2):328-338. doi: 10.1158/1078-0432.CCR-24-2396.

The Game is Afoot - Seeking Early-Stage Lung Cancer Circulating Tumor DNA.行动开始——寻找早期肺癌循环肿瘤DNA

J Thorac Oncol. 2024 Nov;19(11):1479-1481. doi: 10.1016/j.jtho.2024.08.014.

The Society of Thoracic Surgeons Expert Consensus on the Multidisciplinary Management and Resectability of Locally Advanced Non-small Cell Lung Cancer.胸外科医师协会关于局部晚期非小细胞肺癌多学科管理与可切除性的专家共识

Ann Thorac Surg. 2025 Jan;119(1):16-33. doi: 10.1016/j.athoracsur.2024.09.041. Epub 2024 Oct 17.

Lancet Oncol. 2024 Nov;25(11):1453-1464. doi: 10.1016/S1470-2045(24)00498-4. Epub 2024 Oct 14.

Perioperative Nivolumab in Resectable Lung Cancer.可切除肺癌的围手术期纳武利尤单抗。

N Engl J Med. 2024 May 16;390(19):1756-1769. doi: 10.1056/NEJMoa2311926.

Neoadjuvant-Adjuvant vs Neoadjuvant-Only PD-1 and PD-L1 Inhibitors for Patients With Resectable NSCLC: An Indirect Meta-Analysis.新辅助-辅助与新辅助单药 PD-1/PD-L1 抑制剂治疗可切除 NSCLC 患者的疗效比较：一项间接荟萃分析。

JAMA Netw Open. 2024 Mar 4;7(3):e241285. doi: 10.1001/jamanetworkopen.2024.1285.

The International Association for the Study of Lung Cancer Lung Cancer Staging Project: Proposals for Revision of the TNM Stage Groups in the Forthcoming (Ninth) Edition of the TNM Classification for Lung Cancer.国际肺癌研究协会肺癌分期项目：对即将发布的（第九版）肺癌 TNM 分类中 TNM 分期组的修订建议。

J Thorac Oncol. 2024 Jul;19(7):1007-1027. doi: 10.1016/j.jtho.2024.02.011. Epub 2024 Mar 4.

Perioperative Toripalimab Plus Chemotherapy for Patients With Resectable Non-Small Cell Lung Cancer: The Neotorch Randomized Clinical Trial.可切除非小细胞肺癌患者围手术期替雷利珠单抗联合化疗：Neotorch 随机临床试验。

JAMA. 2024 Jan 16;331(3):201-211. doi: 10.1001/jama.2023.24735.

Resectability versus Operability in Early-Stage Non-Small Cell Lung Cancer.早期非小细胞肺癌的可切除性与可手术性

Curr Oncol Rep. 2024 Jan;26(1):55-64. doi: 10.1007/s11912-023-01477-3. Epub 2023 Dec 22.

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验